

KH PHARMA SOLUTIONS LTD

DIRECTOR'S REPORT AND ABRIDGED FINANCIAL STATEMENTS

FOR THE YEAR ENDED

31 MARCH 2023

WEDNESDAY



AC50MZ08

A27

14/06/2023

#104

COMPANIES HOUSE

KH PHARMA SOLUTIONS LTD

COMPANY INFORMATION

DIRECTOR: M. K. Holford

COMPANY NUMBER: 10385640 (England and Wales)

REGISTERED OFFICE: 1-7 Park Road
Caterham
Surrey
CR3 5TB

ACCOUNTANTS: Peters & Co.
1-7 Park Road
Caterham
Surrey
CR3 5TB

KH PHARMA SOLUTIONS LTD

CONTENTS

	<u>Page</u>
Director's Report	1
Abridged Balance Sheet	2
Notes to the Abridged Financial Statements	3 - 4

KH PHARMA SOLUTIONS LTD

DIRECTOR'S REPORT FOR THE YEAR ENDED 31 MARCH 2023

The director presents her report and abridged financial statements for the year ended 31 March 2023.

Principal Activity

The company's principal activity during the year was that of Pharmaceutical Marketing Solution Providers.

Directors

The director who served during the year was:

M. K. Holford

Director's responsibilities statement

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable law and regulation.

Company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable her to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small Company Regime

This report has been prepared taking advantage of the exemptions for small companies within Part 15 of the Companies Act 2006.

This report was approved by the Director on 6 June 2023:



.....
M. K. Holford
Director

KH PHARMA SOLUTIONS LTD

ABRIDGED BALANCE SHEET AT 31 MARCH 2023

	<u>NOTES</u>	<u>2023</u>	<u>2022</u>
		£	£
<u>FIXED ASSETS</u>			
Tangible Assets	3	859	1,145
<u>CURRENT ASSETS</u>			
Debtors		14,926	9,967
Cash at Bank		44,993	52,113
		<u>59,919</u>	<u>62,080</u>
<u>CREDITORS:</u> Amounts falling due within one year:		<u>(27,158)</u>	<u>(27,029)</u>
Net Current Assets		<u>32,761</u>	<u>35,051</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>33,620</u>	<u>36,196</u>
<u>PROVISIONS FOR LIABILITIES</u>			
Deferred Taxation		<u>(163)</u>	<u>(218)</u>
		<u>£ 33,457</u>	<u>£ 35,978</u>
<u>CAPITAL AND RESERVES</u>			
Called Up Share Capital		100	100
Profit and Loss Account		33,357	35,878
SHAREHOLDER'S FUNDS		<u>£ 33,457</u>	<u>£ 35,978</u>

All the members have consented to the preparation of abridged financial statements for the year ended 31 March 2023, in accordance with the Companies Act 2006, s.444(2A).

For the financial year ended 31 March 2023, the company was entitled to exemption from audit under Companies Act 2006 s.477 relating to small companies and the members have not required the company to obtain an audit of its accounts for the year in question in accordance with Companies Act 2006 s.476. The director acknowledges her responsibility for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The abridged financial statements of KH Pharma Solutions Ltd, which have been prepared in accordance with the special provisions relating to companies subject to the small companies' regime within the Companies Act 2006, Pt.15, were approved by the Director on 6 June 2023.

The director of the company has elected not to include a copy of the income statement within the Financial Statements.



M. K. Holford
Director
KH PHARMA SOLUTIONS LTD

Company Number: 10385640 (England and Wales)

The Notes on pages 3 and 4 form part of these Financial Statements.

KH PHARMA SOLUTIONS LTD

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

1. ACCOUNTING POLICIES

General information

KH Pharma Solutions Ltd (Company Number: 10385640) is a private company limited by shares and incorporated in England and Wales. Its registered office is 1-7 Park Road, Caterham, Surrey CR3 5TB.

The abridged financial statements have been prepared in accordance with FRS 102 Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006, including the provisions permitting an abridged profit and loss account and balance sheet to be prepared.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is reduced for estimated customer returns, rebates and other similar allowances.

Tangible assets

Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on a reducing balance basis at a rate of 25% per annum.

At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of the asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Taxation

Taxation represents the sum of tax currently payable and deferred tax.

The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on all timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Pensions

The company makes pension contributions to the personal pension scheme of the director. This scheme is externally funded to the company and accordingly, is not part of a corporate scheme requiring actuarial valuation.

KH PHARMA SOLUTIONS LTD

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

2. EMPLOYEES

The average number of persons employed by the company (including directors) during the year was 1 (2022: 1).

3. TANGIBLE ASSETS

	<u>TOTAL</u>
<u>COST</u>	£
At 31 March 2023	<u>3,766</u>
<u>DEPRECIATION</u>	
At 1 April 2022	2,621
Charge for the year	<u>286</u>
At 31 March 2023	<u>2,907</u>
<u>NET BOOK VALUE:</u>	
At 31 March 2023	<u>£ 859</u>
At 31 March 2022	<u>£ 1,145</u>

4. DIVIDENDS

	<u>2023</u>	<u>2022</u>
Amounts recognised as distributions to equity holders in the year		
Interim Dividend for the year ended 31 March 2023 of £750 per share (2022: £1,200 per share)	<u>£75,000</u>	<u>£120,000</u>